See more : Bureau Veritas SA (BVRDF) Income Statement Analysis – Financial Results
Complete financial analysis of Sartorius Stedim Biotech S.A. (SDMHF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Sartorius Stedim Biotech S.A., a leading company in the Medical – Instruments & Supplies industry within the Healthcare sector.
- Probi AB (publ) (PROB.ST) Income Statement Analysis – Financial Results
- Nippon Carbon Co., Ltd. (NCRBF) Income Statement Analysis – Financial Results
- FueTrek Co., Ltd. (2468.T) Income Statement Analysis – Financial Results
- MultiCell Technologies, Inc. (MCET) Income Statement Analysis – Financial Results
- LungLife AI, Inc. (LLAI.L) Income Statement Analysis – Financial Results
Sartorius Stedim Biotech S.A. (SDMHF)
About Sartorius Stedim Biotech S.A.
Sartorius Stedim Biotech S.A. produces and sells instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, filtration, purification, and fluid management services; single-use and reusable hollow-fiber membrane devices, as well as presterilized assemblies for cell and gene therapy applications; and cell harvesting and various other solutions for intensified bioprocesses. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production. It serves manufacturers of pharmaceuticals, foods, and chemicals, as well as research and development laboratories. The company was founded in 1870 and is headquartered in Aubagne, France. Sartorius Stedim Biotech S.A. is a subsidiary of Sartorius AG.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.78B | 3.49B | 2.89B | 1.91B | 1.44B | 1.21B | 1.08B | 1.05B | 884.33M | 683.52M | 588.38M | 543.96M | 477.30M | 432.95M | 401.23M | 368.00M | 268.84M | 521.05M | 484.30M |
| Cost of Revenue | 1.54B | 1.66B | 1.33B | 907.35M | 692.22M | 582.59M | 526.21M | 524.79M | 432.55M | 341.87M | 295.25M | 269.46M | 238.88M | 217.29M | 210.90M | 192.19M | 149.43M | 275.38M | 257.81M |
| Gross Profit | 1.23B | 1.83B | 1.55B | 1.00B | 748.35M | 629.56M | 554.83M | 526.82M | 451.79M | 341.65M | 293.13M | 274.51M | 238.42M | 215.66M | 190.33M | 175.81M | 119.41M | 245.68M | 226.49M |
| Gross Profit Ratio | 44.44% | 52.52% | 53.79% | 52.50% | 51.95% | 51.94% | 51.32% | 50.10% | 51.09% | 49.98% | 49.82% | 50.46% | 49.95% | 49.81% | 47.44% | 47.77% | 44.42% | 47.15% | 46.77% |
| Research & Development | 153.10M | 132.40M | 110.49M | 84.45M | 79.22M | 60.62M | 53.21M | 47.54M | 41.53M | 38.56M | 36.00M | 30.97M | 28.58M | 27.82M | 24.49M | 24.55M | 18.92M | 35.53M | 32.70M |
| General & Administrative | 167.10M | 154.70M | 126.12M | 95.49M | 76.22M | 67.00M | 61.69M | 56.47M | 48.91M | 38.65M | 30.02M | 29.29M | 26.33M | 24.89M | 24.42M | 23.34M | 16.02M | 34.18M | 36.31M |
| Selling & Marketing | 449.10M | 446.50M | 405.65M | 296.05M | 240.59M | 215.21M | 195.24M | 186.60M | 167.19M | 144.30M | 128.67M | 113.59M | 100.13M | 94.79M | 84.51M | 87.89M | 59.90M | -123.48M | -118.79M |
| SG&A | 616.20M | 601.20M | 531.76M | 391.54M | 316.81M | 282.21M | 256.93M | 243.07M | 216.10M | 182.95M | 158.70M | 142.87M | 126.46M | 119.68M | 108.93M | 111.23M | 75.92M | -89.30M | -82.48M |
| Other Expenses | 0.00 | 1.70M | 1.75M | 784.00K | 601.00K | -1.88M | -1.30M | 5.81M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 749.00M | 751.70M | 670.02M | 499.88M | 399.56M | 342.04M | 303.45M | 285.08M | 254.14M | 219.08M | 187.69M | 180.63M | 167.27M | 155.76M | 141.72M | 25.00K | 105.49M | 435.00K | 4.96M |
| Cost & Expenses | 2.31B | 2.41B | 2.00B | 1.41B | 1.09B | 924.63M | 829.66M | 809.87M | 686.69M | 560.96M | 482.94M | 450.08M | 406.15M | 373.05M | 352.62M | 192.21M | 254.92M | 275.81M | 262.77M |
| Interest Income | 6.20M | 500.00K | 276.00K | 509.00K | 336.00K | 385.00K | 274.00K | 127.00K | 1.43M | 423.00K | 168.00K | 1.03M | 978.00K | 431.00K | 354.00K | 607.00K | 101.00K | 6.42M | 8.63M |
| Interest Expense | 117.00M | 18.60M | 10.40M | 6.82M | 4.61M | 3.99M | 4.42M | 4.41M | 4.20M | 6.12M | 4.83M | 5.41M | 7.47M | 4.34M | 7.30M | 13.13M | 6.37M | 235.00K | 152.00K |
| Depreciation & Amortization | 237.60M | 181.70M | 141.56M | 101.69M | 73.37M | 60.91M | 50.68M | 44.69M | 39.86M | 35.56M | 30.56M | 25.87M | 24.48M | 22.98M | 22.69M | 20.90M | 15.25M | 19.21M | 18.49M |
| EBITDA | 755.70M | 1.23B | 798.70M | 569.20M | 416.98M | 349.46M | 275.71M | 280.27M | 213.73M | 156.21M | 129.83M | 113.36M | 96.62M | 83.31M | 71.65M | 55.23M | 29.27M | 65.32M | 53.82M |
| EBITDA Ratio | 27.23% | 35.29% | 28.57% | 32.66% | 28.95% | 28.03% | 27.68% | 26.65% | 25.08% | 22.85% | 22.69% | 21.91% | 20.24% | 19.24% | 17.86% | 15.01% | 10.89% | 12.54% | 11.11% |
| Operating Income | 484.50M | 995.20M | 865.42M | 471.81M | 332.03M | 300.23M | 221.70M | 225.92M | 184.53M | 120.37M | 101.35M | 87.20M | 71.16M | 59.89M | 48.61M | 33.73M | 13.91M | 245.24M | 221.53M |
| Operating Income Ratio | 17.46% | 28.49% | 29.98% | 24.70% | 23.05% | 24.77% | 20.51% | 21.48% | 20.87% | 17.61% | 17.22% | 16.03% | 14.91% | 13.83% | 12.12% | 9.17% | 5.17% | 47.07% | 45.74% |
| Total Other Income/Expenses | -83.40M | 135.20M | -218.72M | -11.02M | -24.97M | 2.80M | -18.32M | -12.93M | -14.85M | -15.26M | -6.90M | -3.74M | -6.49M | -3.91M | -6.94M | -12.52M | -6.27M | -199.37M | -186.35M |
| Income Before Tax | 401.10M | 1.13B | 646.72M | 482.63M | 317.61M | 284.55M | 220.61M | 212.99M | 169.68M | 105.11M | 94.45M | 83.46M | 64.67M | 55.99M | 41.67M | 21.21M | 7.65M | 45.87M | 35.18M |
| Income Before Tax Ratio | 14.45% | 32.36% | 22.40% | 25.27% | 22.05% | 23.47% | 20.41% | 20.25% | 19.19% | 15.38% | 16.05% | 15.34% | 13.55% | 12.93% | 10.38% | 5.76% | 2.84% | 8.80% | 7.26% |
| Income Tax Expense | 89.00M | 250.50M | 232.41M | 122.11M | 81.42M | 74.59M | 56.85M | 57.11M | 50.18M | 31.38M | 26.97M | 25.57M | 21.48M | 17.48M | 12.58M | 8.10M | 2.91M | -15.63M | -12.11M |
| Net Income | 309.70M | 876.10M | 414.40M | 335.93M | 234.50M | 208.05M | 161.09M | 153.68M | 118.00M | 72.44M | 66.28M | 56.76M | 43.05M | 38.51M | 29.09M | 13.09M | 4.74M | 29.02M | 22.11M |
| Net Income Ratio | 11.16% | 25.08% | 14.35% | 17.59% | 16.28% | 17.16% | 14.90% | 14.61% | 13.34% | 10.60% | 11.26% | 10.43% | 9.02% | 8.90% | 7.25% | 3.56% | 1.76% | 5.57% | 4.57% |
| EPS | 3.36 | 9.51 | 4.50 | 3.64 | 2.54 | 2.26 | 1.75 | 1.67 | 1.28 | 0.79 | 0.72 | 0.62 | 0.47 | 0.40 | 0.28 | 0.13 | 0.07 | 0.28 | 0.22 |
| EPS Diluted | 3.36 | 9.51 | 4.50 | 3.64 | 2.54 | 2.26 | 1.75 | 1.67 | 1.28 | 0.79 | 0.72 | 0.62 | 0.47 | 0.40 | 0.28 | 0.13 | 0.07 | 0.28 | 0.22 |
| Weighted Avg Shares Out | 92.16M | 92.16M | 92.18M | 92.18M | 92.18M | 92.18M | 92.18M | 92.17M | 92.20M | 92.11M | 92.06M | 92.00M | 91.94M | 96.48M | 101.84M | 101.53M | 72.13M | 102.28M | 102.28M |
| Weighted Avg Shares Out (Dil) | 92.16M | 92.16M | 92.18M | 92.18M | 92.18M | 92.18M | 92.18M | 92.17M | 92.20M | 92.11M | 92.20M | 92.15M | 92.18M | 96.80M | 102.40M | 102.40M | 73.21M | 102.28M | 102.28M |
Sartorius Stedim Biotech S.A. (SDMHF) Q3 2024 Earnings Call Transcript
Sartorius Stedim Biotech S.A. (SDMHF) H1 2024 Earnings Call Transcript
Sartorius Stedim Biotech S.A. (SDMHF) Q4 2023 Earnings Call Transcript
10 stocks for investors looking for ‘wonderful companies at a fair price'
Sartorius Stedim Biotech S.A. (SDMHF) Q3 2023 Earnings Call Transcript
Sartorius Stedim Biotech S.A. (SDMHF) Q2 2023 Earnings Call Transcript
Sartorius, Sartorius Stedim shares fall after Polyplus acquisition
Sartorius Stedim Biotech S.A. (SDMHF) Q4 2022 Earnings Call Transcript
Source: https://incomestatements.info
Category: Stock Reports